3 Dividend-Paying Pharmaceutical Stocks Rated Strong Buy in the POWR Ratings

NYSE: PFE | Pfizer Inc. News, Ratings, and Charts

PFE – Since the equity markets are expected to remain uncertain in the near term on several concerns, we think it could be wise to scoop up dividend-paying pharmaceutical stocks, given the industry’s defensive nature. Betting on dividend-paying pharmaceutical stocks Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb (BMY) should help generate a steady income stream to dodge market volatility. These stocks also have an overall ‘Strong Buy’ rating in our proprietary rating system. Let’s discuss.

After the three major stock market indexes posted three straight days of gains, the S&P 500 and Nasdaq Composite ended lower yesterday ahead of key inflation data and nagging COVID-19 omicron variant fears. Amid this market uncertainty, we think it could be wise to bet on quality pharmaceutical stocks, given the industry’s defensive nature. Companies in this space typically witness steady demand for their products and services irrespective of the economic conditions.

Moreover, the industry is expected to grow going forward as the population ages and chronic diseases rise. According to a LINCHPIN report, the pharmaceutical industry is expected to increase to $1.5 trillion by 2023.

Therefore, we think dividend-paying quality pharmaceutical stocks Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), and Bristol-Myers Squibb Company (BMY) could be solid additions to one’s portfolio now to secure a steady income stream. They each have an overall Strong Buy rating in our POWR Ratings system.

Pfizer Inc. (PFE)

New York City-based biopharmaceutical company PFE offers medicines and vaccines in various therapeutic areas, including cardiovascular, metabolic, pain, biologics, small molecules, and immunotherapies. In addition, yesterday, the U.S. FDA expanded the Emergency Use Authorization (EUA) of a booster dose of PFE and BioNTech SE’s (BNTX) COVID-19 Vaccine to include individuals 16 years of age and older.

On November 17, 2021, PFE announced the successful completion of its acquisition of Trillium Therapeutics, a clinical-stage immuno-oncology company that is developing innovative therapies for cancer treatment. Chris Boshoff, MD, PhD, Chief Development Officer, Oncology, PFE Global Product Development, said, “Today’s announcement combines Pfizer’s research and global development capabilities with Trillium’s innovative discoveries, allowing us to accelerate breakthroughs that change patients’ lives.”

PFE’s revenues increased 134.4% year-over-year to $24.09 billion for its  fiscal third quarter, ended September 30, 2021. While its adjusted income increased 132.7% year-over-year to $7.69 billion, its adjusted EPS came in at $1.34, up 127.1% year-over-year.

PFE has been paying dividends consistently since 1980. Over the last three years, the company’s payout has grown at a 6.56% CAGR. While the four-year average dividend yield for PFE is 3.69%, the current dividend translates to a 3% yield. It paid a $0.39 per share quarterly dividend on December 6, 2021.

Analysts expect PFE’s revenue to increase 9.5% year-over-year to $808.32 billion for its fiscal year 2022. In addition, its EPS is expected to grow 23.8% year-over-year to $47.25 in the next year. Over the past nine months, the stock has gained 51.2% in price to close yesterday’s trading session at $52.08.

PFE’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, which indicates a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.

PFE has an A grade for Growth and a B grade for Value, Sentiment, and Quality. Within the Medical – Pharmaceuticals industry, it is ranked #7 of 195 stocks. Click here to see the additional POWR Ratings for Momentum and Stability for PFE.

Merck & Co., Inc. (MRK)

MRK operates as a healthcare company worldwide. The Kenilworth, N.J-based company operates through two segments: Pharmaceutical and Animal Health segments. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products, while its Animal Health segment develops, manufactures, and markets a wide range of veterinary pharmaceutical and vaccine products.

On November 22, 2021, MRK announced the successful completion of its acquisition of Acceleron Pharma Inc. (XLRN). Rob Davis, the company’s CEO and the president said, “Fuelled by Acceleron’s ground-breaking research, we are excited to explore the opportunities and possibilities ahead to reach even more patients by addressing this critical health need.”

MRK’s sales increased 20.4% year-over-year to $13.15 billion for its fiscal third quarter, ended September 30, 2021. The company’s non-GAAP net income came in at $4.44 billion, up 27.3% year-over-year. In addition, its non-GAAP EPS was  $1.75, representing a 27.7% year-over-year rise.

On November 30, MRK announced a $0.69 quarterly dividend per share for the first quarter of 2022. The company started paying dividends in 1990. Over the last three years, MRK’s dividend payout has grown at an 11.53%  CAGR. While the four-year average dividend yield for MRK is 2.94%, the current dividend translates to a 3.79% yield.

For its fiscal year 2022, analysts expect MRK’s revenue to be $56.45 billion, representing a 15.6% year-over-year rise. The company’s EPS is expected to increase 28.3% year-over-year to $5.81 in its fiscal year 2021. The stock has gained 6.5% in price since hitting its 52-week low of $68.44 on March 4, 2021, to close yesterday’s trading session at $72.86.

MRK’s POWR Ratings reflect this promising outlook. The stock has an overall A rating, equating to a Strong Buy in our POWR Rating system. Also, the stock has an A grade for Growth and a B grade for Value and Quality. Click here to see the additional POWR Ratings for MRK (Momentum, Stability, and Sentiment). Again, MRK is ranked #3 in the Medical – Pharmaceuticals industry.

Bristol-Myers Squibb Company (BMY)

BMY develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The New York City-based company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes.

On October 27, 2021, Giovanni Caforio, M.D., board chair and CEO, BMY, said, “Our teams advanced the product portfolio and achieved significant regulatory and clinical milestones, including for the fixed-dose combination of relatlimab and nivolumab. Our deep and diverse product pipeline, commercial execution and financial flexibility provide a strong foundation that is enabling the company to bring new medicines that benefit patients with serious unmet needs, drive in-line product performance and deliver sustained growth.”

BMY’s total revenues increased 10.3% year-over-year to $11.62 billion for its fiscal third quarter, ended September 30, 2021. The company’s net product sales also increased 10.3% year-over-year to $11.24 billion. And its non-GAAP EPS increased 22.7% year-over-year to $2.

BMY started paying dividends in 1970. The stock’s dividend payout has grown at a 7% CAGR over the last three years. While BMY’s four-year average dividend yield is 3%, its current dividend translates to a 3.41% yield. The company paid a $0.49 quarterly dividend on November 1, 2021.

For its fiscal year 2021, analysts expect BMY’s revenue to be $46.53 billion, representing a 9.4% year-over-year rise. In addition, the company’s EPS is expected to increase 16.5% year-over-year to $7.5 this year. Also, it surpassed the consensus EPS estimates in three of the trailing four quarters. The stock has gained 8.1% in price since hitting its 52-week low of $53.22 on November 30, 2021, to close yesterday’s trading session at $57.54.

BMY’s POWR Ratings reflect this promising outlook. The stock has an overall A rating, which equates to  a Strong Buy in our POWR Rating system. Also, the stock has an A grade for Value and a B grade for Growth and Quality. Click here to see BMY’s Momentum, Stability, and Sentiment rating. BMY is ranked #11 in the Medical – Pharmaceuticals industry.


PFE shares were trading at $52.42 per share on Friday afternoon, up $0.34 (+0.65%). Year-to-date, PFE has gained 47.98%, versus a 26.40% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
PFEGet RatingGet RatingGet Rating
MRKGet RatingGet RatingGet Rating
BMYGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Bears Back in Charge...What Happens Next?

A month ago the bulls were claiming victory as they created a charge back over 4,000 for the S&P 500 (SPY). Since then that false narrative has been peeled away and investors are more honestly looking at the bleak outlook formed by high inflation and a hawkish Fed. That explains why we are back retesting the June lows. Now we have to ponder what comes next and how to trade our way to profits. Read on below for the full story...

:  |  News, Ratings, and Charts

2 Warren Buffett Stocks to Buy and Never Sell

Warren Buffett’s long-term value investing strategy serves as a guide for investors to ensure high returns. With the market volatility becoming more severe after the Fed’s recent interest rate hike, Buffett’s top holdings could be ideal investments for long-term investors. To that end, buying and holding Johnson & Johnson (JNJ) and United Parcel Service (UPS) could be wise. Continue reading…

:  |  News, Ratings, and Charts

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns despite market uncertainties, could be ideal buys now. Keep reading…

:  |  News, Ratings, and Charts

The Most Sought-After Tech Stock to Buy Right Now

Shares of Microsoft (MSFT) have shed more than 25% year-to-date, with the rising interest rates causing a massive tech sell-off. However, the current low price level allows long-term investors to take a position in the stock to benefit from its solid growth prospects. The company has guided double-digit growth for fiscal 2023. Moreover, MSFT has been increasingly paying dividends, which should help generate a steady income stream. Read more…

:  |  News, Ratings, and Charts

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns despite market uncertainties, could be ideal buys now. Keep reading…

Read More Stories

More Pfizer Inc. (PFE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PFE News